The continued emergence of antimicrobial resistance represents one of the most significant challenges in modern medicine. Many existing therapies rely on mechanisms that are increasingly compromised by pathogen adaptation, while the discovery of new antimicrobial classes remains complex and resource-intensive. NexAmins Bio is developing an alternative strategy focused on: 1) Understanding pathogen-specific metabolic dependencies. 2) Identifying validated therapeutic targets. 3) Designing molecules guided by biological mechanisms. 4) Optimizing ligand–target interactions. 5) Developing innovative approaches against persistent and intracellular infections. Our platform integrates biological discovery with rational molecular engineering to accelerate the path from fundamental research to therapeutic innovation.

Many pathogens rely on specialized metabolic networks to survive, replicate, and adapt within host environments. NexAmins Bio focuses on discovering these biological dependencies and evaluating their potential as therapeutic targets. Our research strategy includes: 1) Metabolic pathway analysis. 2) Identification of essential survival mechanisms. 3) Comparative pathogen–host biology. 4) Validation of biologically meaningful targets. Beyond advancing our internal therapeutic pipeline, the NexAmins Bio Research Team actively publishes scientific research in peer-reviewed and specialized journals, ensuring our innovation platform remains grounded in the latest advances in synthetic biology, microbial metabolism, and anti-infective drug discovery.